BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will release its third quarter 2017 financial results on Thursday, November 2, 2017 before the opening of U.S. financial markets.

Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:

Date   November 2, 2017
Time   9:00 a.m. EDT
Toll free (U.S.)   (888) 372-9592
Webcast (live and replay)   www.bioscrip.com
     

A replay of the conference call will be available two hours after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 1115410.

About BioScrip

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Investor Contacts    
     
Stephen Deitsch    David Clair
Chief Financial Officer & Treasurer   ICR, Inc.
T: (720) 697-5200   T: (646) 277-1266
stephen.deitsch@bioscrip.com    david.clair@icrinc.com 
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioPlus Acquisition Charts.
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioPlus Acquisition Charts.